Background Several multi-attribute utility instruments (MAUIs) are available from which
utilities can be derived for use in cost-utility analysis (CUA). This study provides a review of …

Background China has achieved near-universal health coverage (UHC) for 95 percent of its
population (> 1.3 billion lives) as a result of healthcare reforms that began in 2009. However …

Abstract Objectives In Japan, cost-effectiveness evaluation was implemented on a trial basis
from fiscal year 2016. The results will be applied to the future repricing of drugs and medical …

Introduction Productivity loss may contribute to a large proportion of costs of health
conditions in an economic evaluation from a societal perspective, but there is currently a …

Background and objectives: Governments in Asia Pacific (APAC) are increasingly using
pharmaceutical pricing strategies to contain rising healthcare costs. The objective of this …

This study describes the process and results of drug reimbursement decision-making in
South Korea and evaluates its performance from the perspectives of the various …

Purpose Sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor
(ARNI), is a possible treatment option for chronic heart failure patients with reduced ejection …

Objectives This study aimed to provide an exhaustive description of criteria and
methodological recommendations for evaluating them in health technology assessment …

Objectives The aim of this study was to review the current evaluation and funding processes
for new drugs in different developed countries, to provide a comparative framework with …

Background The most appropriate preference-based health-related quality of life (HRQoL)
instruments for trials or research studies that ascertain the consequences of individuals born …